Novavax Inc. and its partner Serum Institute of India announced that their vaccine has received emergency use authorization in Indonesia for the first time anywhere in the world. Novavax Inc. anticipates authorities in India, the Philippines, and other countries to make a judgement on its COVID-19 vaccine in “weeks,” according to its CEO.
While the company also notified that it has filed an application for emergency use of the vaccine in Canada and the European Medicines Agency, shares of Novavax rose to 11% before the opening bell. For Indonesia, the vaccine will be manufactured by Serum Institute of India, the largest vaccine manufacturer in the world and sold under its brand name Covovax.
Initial shipments to Indonesia are scheduled to begin soon, according to Novavax. The World Health Organization (WHO) is also assessing Novavax’s regulatory application. The company hopes that it will be completed in the coming weeks, according to Chief Executive Stanley Erck.
Also, know that US Allows Entry Of COVAXIN-Jabbed Indians
If the WHO gives its approval, Novavax will be able to start distributing doses to the COVAX programme, which provides vaccines to low-income nations. COVAX, which is co-led by the WHO, has committed to receiving more than 1.1 billion doses from Novavax and the Serum Institute of India.
On Friday, the firm said that it was prepared to seek regulatory clearance for a rollout in Japan early next year, in collaboration with its Japanese partner Takeda Pharmaceutical Co. Novavax has postponed seeking FDA clearance in the United States, and Politico reported last month that the business was experiencing production and quality issues.
In a major late-stage U.S.-based trial, the Novavax injection was proven to be more than 90% effective, including against a number of worrying coronavirus types. In Phase 3 research, Novavax was 96.4 per cent effective in preventing COVID-19 caused by the original strain of the virus. Likewise, in similar testing, both the Moderna and Pfizer vaccines demonstrated efficacy in the mid-90 per cent range.
